AB067. New drug development for the use of PARP1-E2F1 transcriptional inhibitors in the treatment of glioblastoma
Both in silico and in vitro results indicate that inhibition of PARP1-E2F1 transcriptional activity may provide a new rationale for designing novel therapeutic approaches for the treatment of GBM.
Authors
- David Moreira (ORCID: https://orcid.org/0000-0002-4579-3310)
- Vı́ctor M. Arce (ORCID: https://orcid.org/0000-0003-2391-6217)
- José A. Costoya
- Laura Porres-Ventin
- Jose A. Zumalave
- Pablo Iglesias (ORCID: https://orcid.org/0000-0003-2506-5313)
- Lara Gonzalez-Rendo
Institutions
- Center for Research in Molecular Medicine and Chronic Diseases (ES)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/cco-24-ab067
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00